LEGN241220P100000
- 0.00
- 0.000.00%
Legend Biotech Newsroom
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
Duan Yongping and Buffett have a "soul resonance" in their third-quarter operations, and Li Lu re-enters an oil & gas stock.
For nvidia, Bridgewater, Jinglin, Baillie Gifford, and "Cathie Wood" are all reducing their shareholding, and everyone is quietly united in missing the opportunity of nvidia reaching the top of the market cap.
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $82
Morgan Stanley Remains a Buy on Legend Biotech (LEGN)
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Top private equity funds in China expose the 'US stock report': the proportion of Chinese concept stocks continues to rise, with PDD Holdings and Apple being the focus of differences in components.
In the third quarter of this year, most Chinese private equity firms, such as Hillhouse, Gao Yi, and Jinglin, remained focused on Chinese concept stocks. However, Hillhouse and Jinglin chose to reduce their shareholding in pdd holdings, while Gao Yi opted to continue increasing its stake in pdd holdings.
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.
Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech (LEGN) Gets a Buy From Truist Financial
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $83
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
Legend Biotech's CARVYKTI Advances and Strategic Positioning Amid Financial Resilience
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)
Express News | Legend Biotech Corp : Piper Sandler Cuts Target Price to $78 From $90